Zusammenfassung
Stärkste Stoffgruppen unter den Dermatika sind die Corticosteroidexterna, gefolgt von den Wundbehandlungsmitteln, den topischen Antiphlogistika und Antipruriginosa sowie den Basistherapeutika und Hautschutzmitteln.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abadjieva, T.I. (2000): Treatment of androgenetic alopecia in females in reproductive age with topical estradiolbenzoate, prednisolon and salicylic acid. Folia Med. (Plovdiv) 42: 26–29.
Altmeyer P.J., Matthes U., Pawlak F., Hoffmann K., Frosch P.J., Ruppert P. et al. (1994): Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J. Am. Acad. Dermatol. 30: 977–981.
Ammon H.P.T., Sabieraj J., Kaul R. (1996): Kamille. Mechanismus der antiphlogistischen Wirkung von Kamillenextrakten und -inhaltsstoffen. Dtsch. Apoth. Ztg. 136: 1821–1834.
Arzneimittelkommission der deutschen Ärzteschaft (1999): Nutzen und Risiken durch Fumarsäure-Ester bei der Therapie der Psoriasis. Dtsch. Ärztebl. 96: A-721.
Asadullah K., Schmid H., Friedrich M., Randow F., Volk H.-D., Sterry W., Döcke W.-D. (1997): Influence of monomethylfumarate on monocytic cytokine formation — explanation for adverse and therapeutic effects in psoriasis? Arch. Dermatol. Res. 289: 623–630.
Ashcroft D.M., Li Wan Po A., Griffiths C.E.M. (2000a): Therapeutic strategies for psoriasis. J. Clin. Pharm. Ther. 25: 1–10.
Ashcroft D.M., Li Wan Po A., Williams H.C., Griffiths C.E.M. (2000b): Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. Brit. Med. J. 320: 963–967.
Bradley M., Cullum N., Sheldon T. (1999): The debridement of chronic wounds: a systematic review. Health Technol. Assess. 3: 1–78.
Braun-Falco O., Plewig G., Wolff H.H. (1995): Dermatologie und Venerologie, 4. Aufl. Springer-Verlag, Berlin Heidelberg New York.
Brogden R.N., Goa K.L. (1997): Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 53: 511–519.
Bundesgesundheitsamt (1988): Monographie Fumarsäuremonoalkylester, Fumarsäuredialkylester, Fumarsäure und Fumarsäuresalze. Bundesanzeiger vom 11.10.1988, Nr. 191.
Bundesgesundheitsamt (1993): Monographie Steinkohlenteer. Bundesanzeiger 45: 845. Bundesinstitut fĂĽr Arzneimittel und Medizinprodukte (2001): Schreiben vom 1. 6. 2001.
Byrne A., Hnatko G. (1995): Depression associated with isotretinoin therapy. Can. J. Psychiatry 40: 567.
Lather J., Menter A. (2002) Novel therapies for psoriasis. Am. J. Clin. Dermatol. 3: 159–173.
Chaffman M.O. (1999): Topical corticosteroids: A review of properties and principles in therapeutic use. Nurse Practitioner Forum 10: 95–105.
Christiansen J.V., Gadborg E., Kleiter I., Ludvigsen K., Meier C.H., Norholm A. et al. (1977): Efficacy of bufexamac (NFN) cream in skin diseases. A double-blind multicentre trial. Dermatologica 154: 177–184.
Daschner F. (1987): Sind Lokalantibiotika bei Hautinfektionen sinnvoll? Arzneiverordnung 4: 41–46.
De Jong R., Bezemer A.C., Zomerdijk T.P.L., van de Pouw-Kraan T., Ottenhoff T.H.M., Nibbering P.H. (1996): Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 26: 2067–2074.
Deutsche Dermatologische Gesellschaft (1998): Akne und ihre Subtypen. Leitlinien der Deutschen Dermatologischen Gesellschaft. AWMF-Leitlinien-Register Nr.013/017 (http://www.uni-duesseldorf.de)/WWW/AWMF/II/derm-008.htm Eastham J.H. (2001): Postpartum alopecia. Ann. Pharmacother. 35: 255–258.
Feldman S. (2000): Advances in psoriasis treatment. Dermatol. Online J. 6: 4.
Ferguson J. (2002): What is the role of narrowband UVB in the treatment of psoriasis? Photodermal. Photoimmunol. Photomed. 18: 42–43.
Fine J.D., Johnson L. (1988): Evaluation of the efficacy of topical bufexamac in epidermolysis bullosa simplex. A double-blind placebo-controlled crossover trial. Arch. Dermatol. 124: 1669–1672.
Fricke U., Klaus W. (1985): Die neuen Arzneimittel — Wirkungsweise und therapeutischer Stellenwert. Eine Übersicht von Januar 1983–Juni 1984. Offizinpharmazie 10: 1–71.
Fricke U., Klaus W. (1991): Neue Arzneimittel 1990/91. Fortschritte fĂĽr die Arzneimitteltherapie? Wissenschaftliche Verlagsgesellschaft, Stuttgart.
Fricke U., Klaus W. (1992): Neue Arzneimittel 1991/92. Fortschritte fĂĽr die Arzneimitteltherapie? Wissenschaftliche Verlagsgesellschaft, Stuttgart.
Gerritsen M.J., van de Kerkhof P.C., Langner A. (2001): Long-term safety of topical calcitriol 3 microg g(-1) ointment. Br. J. Dermatol. 144 (Suppl. 58): 17–19.
Glass D., Boorman G.C., Stables G.I., Cunliffe W.J., Goode K. (1999): A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0,05%) and erythromycin (2%) with gels containing isotretinoin (0,05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology 199: 242–247.
Gloor M. (1982): Pharmakologie dermatologischer Externa. Springer-Verlag, Berlin Heidelberg New York.
Gniazdowska B., Rueff F., Przybilla B. (1999): Delayed contact hypersensitivity to non-steroidal anti-inflammatory drugs. Contact Dermatitis 40: 63–65.
Gordon P.M., Diffey B.L., Matthews J.N.S., Farr P.M. (1999): A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J. Am. Acad. Dermatol. 41: 728–732.
Greaves M.W., Weinstein G.D. (1995): Treatment of psoriasis. N. Engl. J. Med. 332: 581–588.
Griffiths C.E., Clark C.M., Chalmers R.J., Li Wan Po A., Williams H.C. (2000): A systematic review of treatments for severe psoriasis. Health Technol. Assess. 4: 1–125.
Hahn C., Röseler S., Fritzsche R., Schneider R., Merk H.F. (1993): Allergic contact reaction to dexpanthenol: lymphocyte transformation test and evidence for microsomal-dependent metabolism of the allergen. Contact Dermatitis 28: 81–83.
Hölzle E. (1984): Therapie der Hyperhidrosis. Hautarzt 35: 7–15.
Hornstein O.P.,NĂĽrnberg E. (Hrsg.) (1985): Externe Therapie von Hautkrankheiten. Pharmazeutische and medizinische Praxis. Georg Thieme Verlag, Stuttgart New York.
Hornstein O.P. (1997): Glukokortikosteroide in der Dermatologie: Tag-and Nacht-Therapie vergessen. Dtsch. Ă„rztebl. 94: A-678.
Hughes B.R., Norris J.F., Cunliffe W.J. (1992): A double-blind evaluation of topical isotretinoin 0,05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clin. Exp. Dermatol. 17: 165–168.
Jemec G. B.E., østerlind A. (1994): Cancer in patients treated with coal tar: a longterm follow up study. J. Eur. Acad. Dermatol. Venerol. 3: 153–156.
Knapp U. (1995): Grundlagen der Wundheilung and Wundbehandlung. Med. Monatsschr. Pharm. 18: 219–230.
Korting H.C. (1995): Dermatotherapie: ein Leitfaden. Springer-Verlag, Berlin Heidelberg New York.
Korting H.C., Schäfer-Korting M., Klövekorn W., Klövekorn G., Martin C., Laux P. (1995): Comparative efficacy of hamamelis distillate and hydrocortisone cream in atopic eczema. Eur. J. Clin. Pharmacol. 48: 461–465.
Lamba S., Lebwohl M. (2001): Combination therapy with vitamin D analogues. Br. J. Dermatol. 144 (Suppl. 58): 27–32.
Langner A., Stapór W., Ambroziak M. (2001): Efficacy and tolerance of topical calcitriol 3 microg g(-1) in psoriasis treatment: a review of our experience in Poland. Br. J. Dermatol. 144 (Suppl. 58): 11–16.
Lebwohl M. (1999): The role of salicylic acid in the treatment of psoriasis. Int. J. Dermatol. 38: 16–24.
Lebwohl M. (2002): Should we switch from combination UVA/UVB phototherapy units to narrowband UVB? Photodermal. Photoimmunol. Photomed. 18: 44–46.
Lemmer B., Brune K. (Hrsg.) (2001): FĂĽlgraff Palm Pharmakotherapie, klinische Pharmakologie, 11. Aufl. Urban 0026 Fischer, MĂĽnchen, Jena.
Leung D.Y.M. (2001): Atopic dermatitis and the immune system: The role of super-antigens and bacteria. J. Am. Acad. Dermatol. 45: S13–S16.
Leyden J.J., Hickman J.G., Jarratt M.T., Stewart D.M., Levy S.F. (2001): The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J. Cutan. Med. Surg. 5: 37–42.
Lokkevik E., Skovlund E., Reitan J. B., Hannisdal E., Tanum G. (1996): Skin treatment with Bepanthen cream versus no cream during radiotherapy. Acta Oncol. 35: 1021–1026.
Lookingbill D.P., Chalker D.K., Lindholm J.S., Katz H.I., Kempers S.E., Huerter C.J. et al. (1997): Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J. Am. Acad. Dermatol. 37: 590–595.
Lunan H.N. (1975): Topical treatment of the burn patient. Am. J. Hosp. Pharm. 32: 599–605.
Maddin S. (Hrsg.) (1991): Current Dermatologic Therapy, 2°d ed. W. B. Saunders Comp., Philadelphia.
Maiche A.G., Gröhn P., Mäki-Hokkonen H. (1991): Effect of chamomille cream and almond ointment on acute radiation skin reaction. Acta Oncol. 30: 395–396.
Mason J., Mason A.R., Cork M.J. (2002): Topical preparations for the treatment of psoriasis: a systematic review. Br. J. Dermatol. 146: 351–364.
Merk H.F., Bickers D.R. (1992): Dermatopharmakologie and Dermatotherapie. Blackwell, Berlin.
Murdoch D., Clissold S.P. (1992): Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs 43: 415–429.
Mutschier E., Geisslinger G., Kroemer H.K., Schäfer-Korting M. (2001): Mutschler Arzneimittelwirkungen, 8. Auflage. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
Nieboer C., de Hoop D., van Loenen A.C., Langendijk P.N.J., van Dijk E. (1989): Systemic therapy with fumaric acid derivatives: New possibilities in the treatment of psoriasis. J. Am. Acad. Dermatol. 20: 601–608.
Niedner R. (1998): Kortikoide in der Dermatologie. UNI-MED Verlag, Bremen.
Niedner R., Ziegenmeyer J. (Hrsg.) (1992): Dermatika. Therapeutischer Einsatz, Pharmakologie and Pharmazie. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
N.N. (1997): Therapie der schweren Psoriasis mit Fumaraten. Arzneimittelbrief 31: 57–59.
Nugteren-Huying W.M., van der Schroeff J.G., Hermans J., Suurmond D. (1990): Fumaric acid therapy for psoriasis: A randomized, double-blind, placebo-controlled study. J. Am. Acad. Dermatol. 22: 311–312.
Ockenfels H.M., Schultewolter T., Ockenfels G., Funk R., Goos M. (1998): The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine work. Br. J. Dermatol. 139: 390–395.
Orfanos C.E., Zouboulis C.C., Almond-Roesler B., Geilen C.C. (1997): Current use and future potential role of retinoids in dermatology. Drugs 53: 358–388.
Parfitt K. (ed.) (1999): Martindale: The Complete Drug Reference, 32nd edition. Pharmaceutical Press, London.
Patel B., Siskin S., Krazmien R., Lebwohl M. (1998): Compatibility of calcipotriene with other topical medications. J. Am. Acad. Dermatol. 38: 1010–1011.
Peters D.C., Balfour J.A. (1997): Tacalcitol. Drugs 54: 265–271.
Petersen E.E., Doerr H.W., Gross G., Petzoldt D., Weissenbacher E.R., Wutzler P. (1999): Der Herpes genitalis. Dtsch. Ă„rztebl. 96: A-2358-A2364.
Pfannschmidt N., Bauer R., Kreysel H.W. (1988): Lokale Kombinationstherapie der Akne mit Erythromycin und Tretinoin. Z. Hautkr. 63: 366–368.
Post B., Jänner M. (1971): Indication for tannin therapy in dermatology. Clinical experiences with Tannosynt. Ther. Ggw. 110: 1477–1494.
Raab W. (1984): Psoriasis-Behandlung mit Fumarsäure und Fumarsäureestern. Z. Hautkr. 59: 671–679.
Raborn G.W., McGaw W.T., Grace M., Eng P., Percy J., Samuels S. (1989): Herpes labialis treatment with acyclovir 5% modified aqueous cream: A double-blind, randomized trial. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 67: 676–679.
Ring J., Fröhlich H.H. (1985): Wirkstoffe in der dermatologischen Therapie, 2. Aufl. Springer-Verlag, Berl in Heidelberg.
Rizova E., Corroller M. (2001): Topical calcitriol–studies on local tolerance and systemic safety. Br. J. Dermatol. 144 (Suppl. 58): 3–10.
Savin J. A. (1985): Some guidelines to the use of topical corticosteroids. Brit. Med. J. 290: 1607–1608.
Schäfer-Korting M., Schmid M.H., Korting H.C. (1996): Topical glucocorticoids with improved risk-benefit ratio. Drug Safety 14: 375–385.
Scharfetter-Kochanek K., Meewes C., Eming S., Dissemond J., Hani N., Wenk J., Wlaschek M., Brenneisen P. (1999): Chronische Wunden und Wachstumsfaktoren. Zeitschr. Hautkrankh. H+G 11: 664–672.
Scholz H., Schwabe U. (Hrsg.) (2000): Taschenbuch der Arzneibehandlung — Angewandte Pharmakologie, 12. Aufl. Urban 0026 Fischer, München, Jena.
Schulze-Dirks A., Frosch P.J. (1988): Kontaktallergie auf Dexpanthenol. Hautarzt 39: 375–377.
Seböck B., Bonnekoh B., Geisel J., Mahrle G. (1994): Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur. J. Pharmacol. 270: 79–87.
Simon C., Stille W. (2000): Antibiotika-Therapie in Klinik und Praxis, 10. Aufl., Schattauer, Stuttgart New York.
Stoof T.J., Flier J., Sampat S., Nieboer C., Tensen C.P., Boorsma D.M. (2001): The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br. J. Dermatol. 144: 1114–1120.
Strömberg H.E., Âgren M.S. (1984): Topical zinc oxide treatment improves arterial and venous leg ulcers. Br. J. Dermatol. 111: 461–468.
Sykes N.L., Webster G.F. (1994): Acne. A review of optimum treatment. Drugs 48: 59–70.
Thio H. B., Zomerdijk T.P.L., Oudshoorn C., Kempenaar J., Nibbering P.H., van der Schroeff J.G., Ponec M. (1994): Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes. Br. J. Dermatol. 131: 856–861.
Trauner M.A., Ruben B.S. (1999): Isotretinoin induced rhabdomyolysis? A case report. Dermatol. Online J. 5: 2.
Tronnier H., Haas P.J., Zimmermann T. (1990): Effectiveness and mechanism of action of isoprenaline sulfate and clemastine hydrogen fumarate on histamine wheal-induced pruritus. A placebo-controlled proband study. Derm. Beruf Umwelt 38: 15–18.
Trozak D.J. (1999): Topical corticosteroid therapy in psoriasis vulgaris: Update and new strategies. Cutis 64: 315–318.
Vandermeeren M., Janssens S., Borgers M., Geysen J. (1997): Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 234: 19–23.
Veien N.K., Bjerke J.R., Rossmann-Ringdahl I., Jakobsen H. B. (1997): Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br. J. Dermatol. 137: 581–586.
Walters I. B., Burack L.H., Coven T.R., Gilleaudeau P., Krueger J.G. (1999): Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J. Am. Acad. Dermatol. 40: 893–900.
Warnecke J., Wendt A. (1998): Anti-inflammatory action of pale sulfonated shale oile (ICHTHYOL pale) in UVB erythema test. Inflamm. Res. 47: 75–78.
Walluf-Blume D. (1991): Aufbereitung und Nachzulassung von OTC-Arzneimitteln in den USA 1990. Pharm. Ind. 53: 152–158.
Wiesenauer M. (1987): Homöopathie für Apotheker und Ärzte. Deutscher Apotheker Verlag, Stuttgart.
Wolf-Jürgensen P. (1979): Efficacy of bufexamac cream versus betamethasone vale-rate cream in contact dermatitis: a double-blind trial. Curr. Med. Res. Opin. 5: 779–784.
Zouboulis C.C., Fluhr J.W. (1999): Akne–Aktuelle Aspekte zu Pathophysiologie und Therapie. Pharm. Ztg. 144: 4223–4231.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Fricke, U. (2003). Dermatika und Wundbehandlungsmittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2002. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-11173-4_22
Download citation
DOI: https://doi.org/10.1007/978-3-662-11173-4_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-43624-9
Online ISBN: 978-3-662-11173-4
eBook Packages: Springer Book Archive